bluuebunny/crossref_metadata_2025_split huggingface dataset:
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
Authors: ZINMAN BERNARD , FITCHETT DAVID H. , MATTHEUS MICHAELA , WANNER CHRISTOPH , GEORGE JYOTHIS T. , VEDIN OLA , INZUCCHI SILVIO E. , JOHANSEN ODD ERIK 
Published: June 2019

In EMPA-REG OUTCOME, EMPA in 7020 patients with type 2 diabetes mellitus and CV disease significantly reduced 3P-MACE (14%), CV death (38%), all-cause death (32%) and heart failure hospitalization (HHF) (35%.) In addition, HbA1c was reduced but not associated with increased hypo. We investigated the relationship between on-trial hypo with a range of CV outcomes, using adjusted Cox regression models with time-varying covariate for hypo. We employed two hypo definitions: HYPObroad: time to first symptomatic hypo adverse event (AE) with plasma glucose [PG] ≤ 70mg/dL, any hypo AE with PG &lt; 54mg/dL, or severe hypo AE. HYPOstrict: hypo AE with PG &lt; 54mg/dL, or severe hypo AE.
HYPObroad occurred in 28% of participants in each group, whereasHYPOstrict in 19%.In the placebo group, hypo was associated with an increased risk of HHF using both HYPObroad (HR 1.91, [95% CI: 1.25, 2.93], Fig A) or HYPOstrict (1.72 [1.06, 2.78]) and for myocardial infarction (MI) using only HYPObroad (1.56 [1.06, 2.29], Fig A.) EMPA reduced 3P-MACE, CV and all-cause death, and HHF, regardless of occurrence (Fig B) or severity of hypo (p-for interactions &gt; 0.05).
In conclusion, in this post hoc analysis, hypo was associated with an increased risk of MI and HHF but no other investigated CV outcomes. Hypoglycemia did not influence the cardio-protective effect of EMPA.

Disclosure
B. Zinman: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc. Consultant; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc. D.H. Fitchett: Speaker’s Bureau; Self; Boehringer Ingelheim International GmbH, Lilly Diabetes. Other Relationship; Self; Boehringer Ingelheim International GmbH, Novo Nordisk A/S. M. Mattheus: Employee; Self; Boehringer Ingelheim Pharma GmbH&Co.KG. C. Wanner: Advisory Panel; Self; Bayer AG, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp. Board Member; Self; Boehringer Ingelheim International GmbH. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Mitsubishi Tanabe Pharma Corporation. J.T. George: None. O. Vedin: Employee; Self; Boehringer Ingelheim International GmbH. S.E. Inzucchi: Consultant; Self; vTv Therapeutics, Zafgen, Inc. Other Relationship; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi. O. Johansen: Employee; Self; Boehringer Ingelheim International GmbH.

Funding
Boehringer Ingelheim; Eli Lilly and Company
1595-P: Triglyceride and Glucose (TyG) Index as a Predictor of Mortalities
Authors: KIM KYUNG-SOO , HWANG YOU CHEOL , AHN HONG-YUP , PARK SUNG-WOO , PARK CHEOL-YOUNG 
Published: June 2019

Triglycerides and glucose (TyG) index is a useful marker of insulin resistance and a predictor of nonalcoholic fatty liver disease (NAFLD), incident hypertension, cardiovascular events, and subclinical atherosclerosis. The aim of this study was to evaluate the association between TyG index and mortalities in a Korean population using a large health study database. A total of 318,224 subjects (165,131 men and 153,093 women) in the Kangbuk Samsung Health Study cohort were enrolled. A comprehensive annual or biennial health examination was performed to all subjects from 2002 through 2012. Normal glucose tolerance (NGT) was defined as fasting plasma glucose &lt; 100 mg/dL and HbA1c &lt; 5.7%, and having no history of diabetes. The presence of NAFLD was ascertained by ultrasonography in the absence of other known liver diseases. Mortality data (from 2002 through 2012) were derived from the Korea National Statistical Office.The cumulative overall mortality was 0.51% (1,613 deaths) during a median 5.66-year follow-up. In subject with NGT, higher TyG index was associated with an increased risk of death from all causes (HR 1.12; 95% CI 1.03-1.22), cardiovascular disease (HR 1.26; 95% CI 1.02-1.55), and liver disease (HR 1.26; 95% CI 1.02-1.55) but not from cancer, after adjusting for age, sex, and body mass index. In addition, when we have analyzed according to the presence of NAFLD in this group, higher TyG index was only associated with an increased risk of death from all causes in subject without NAFLD (HR 1.16; 95% CI 1.05-1.29). However, there was no significant association between TyG index and mortalities in subject with prediabetes and diabetes. Interestingly, TyG index was associated with overall mortality in subjects with metabolic syndrome (HR 1.31; 95% CI 1.17-1.47) although it was not associated with specific mortalities. In subjects without metabolic syndrome, TyG index was not associated with death from all and specific causes. The TyG index might predict mortalities in subjects with NGT and metabolic syndrome.

Disclosure
K. Kim: None. Y. Hwang: None. H. Ahn: None. S. Park: None. C. Park: None.
1597-P: Incidence of Diabetes in Young Adult South Asians Compared with Pima Indians
Authors: VENKAT NARAYAN K.M. , KONDAL DIMPLE , KOBES SAYUKO , DEEPA MOHAN , DAYA NATALIE R. , PATEL SHIVANI A. , ANJANA RANJIT MOHAN , STAIMEZ LISA R. , ALI MOHAMMED K. , GUJRAL UNJALI , PRABHAKARAN DORAIRAJ , SHIVASHANKAR ROOPA , KADIR MASOOD , SELVIN ELIZABETH , MOHAN VISWANATHAN , HANSON ROBERT L. , TANDON NIKHIL 
Published: June 2019

South Asians have a high burden of diabetes at younger ages. We compared diabetes risk in South Asians aged 20-44 years living in India (Delhi and Chennai) and Pakistan (Karachi) with Pima Indians, a population with the world’s highest incidence of diabetes. We analyzed prospective cohort data from the Pima Indian Study (Pima, n=1852), and the Center for Cardiometabolic Risk Reduction in South Asia Study (CARRS, South Asians, n=6676). We defined diabetes as fasting glucose ≥126 mg/dl, HbA1c ≥ 6.5%, or medication use. At baseline, on average, the South Asians were less obese than Pima (BMI, kg/m2: 24.4 vs. 33.8; Waist, cms 82.5 vs.107). Age-standardized diabetes incidence (cases/1000 person-years, 95% CI) was lower in South Asians than in Pima (Men: 14.2, 12.2-16.2 vs. 37.3, 31.8-42.8; Women: 14.8, 13.0-16.5 vs. 46.1, 41.2-51.1). Incidence among 20-24 year old were 80% and 87% lower, respectively, among South Asian men and women, but the risk differential narrowed at older ages (Table). In those with BMI &lt;25 kg/m2, the risk of diabetes was over five times higher in South Asian men than in Pima. Among those with BMI ≥30 kg/m2, diabetes incidence in South Asians was nearly as high as in Pima. Intriguingly, diabetes incidence is higher in nonobese South Asian than in Pima men but not in women. In obese South Asians, diabetes incidence is perilously close to that in the Pima, and is a cause for major concern, as obesity levels continue to rise in South Asia.

Disclosure
K. Narayan: None. D. Kondal: None. S. Kobes: None. M. Deepa: None. N.R. Daya: None. S.A. Patel: None. R. Anjana: None. L.R. Staimez: None. M.K. Ali: None. U. Gujral: None. D. Prabhakaran: None. R. Shivashankar: None. M. Kadir: None. E. Selvin: None. V. Mohan: None. R.L. Hanson: None. N. Tandon: None.

Funding
National Heart, Lung, and Blood Institute; Department of Health and Human Services (HHSN268200900026C); United Health Group, Minneapolis, MN; National Institute of Diabetes and Digestive and Kidney Diseases (P30DK111024)
1598-P: Incidence of Diabetes in South Asian Adults in Urban India/Pakistan Compared with Blacks and Whites in U.S.
Authors: VENKAT NARAYAN K.M. , KONDAL DIMPLE , DAYA NATALIE R. , PATEL SHIVANI A. , DEEPA MOHAN , ANJANA RANJIT MOHAN , STAIMEZ LISA R. , GUJRAL UNJALI , KOBES SAYUKO , SHIVASHANKAR ROOPA , ALI MOHAMMED K. , KADIR MASOOD , PRABHAKARAN DORAIRAJ , HANSON ROBERT L. , MOHAN VISWANATHAN , SELVIN ELIZABETH , TANDON NIKHIL 
Published: June 2019

Populations in economic transition have a high diabetes prevalence even at lower body mass indices (BMI). We compared diabetes incidence in South Asians ≥45 years in urban India (Delhi and Chennai) and Pakistan (Karachi) with blacks and whites in U.S. Prospective analyses were done using data from the Center for Cardiometabolic Risk Reduction in South Asia Study (CARRS, South Asians, n=3,136), and the Atherosclerosis Risk in Communities Study (ARIC, blacks, n=3,059; whites, n=9,924). We defined diabetes as fasting glucose ≥126 mg/dl, HbA1c ≥ 6.5%, or medication use. South Asians were less obese than blacks and whites (BMI, kg/m2: 24.9 vs. 28.2 vs. 26.0; Waist, cms 87.5 vs.97.5 vs. 95.2). Age-standardized diabetes incidence (cases/1000 person-years, 95% CI) in South Asian men was similar to blacks and 1.6 times than whites (26.0, 22.2-29.8 vs. 26.2, 22.7-29.7 vs. 16.1, 14.8-17.4); and in South Asian women slightly higher than blacks and 3 times than whites (31.9, 27.5-36.2 vs. 28.6, 25.7-31.6 vs. 11.3, 10.2-12.3). In those with BMI &lt;25 kg/m2, the diabetes risk was 2.6 times higher in South Asian men, and 5.3 times in women than in whites. In those with BMI ≥30 kg/m2, diabetes incidence in South Asian men and women were 2.6 and 2.1 times higher than in whites.
Adults in urban India/Pakistan have higher diabetes incidence than U.S. whites. Even nonobese South Asian adults have markedly higher risk of diabetes compared to whites.

Disclosure
K. Narayan: None. D. Kondal: None. N.R. Daya: None. S.A. Patel: None. M. Deepa: None. R. Anjana: None. L.R. Staimez: None. U. Gujral: None. S. Kobes: None. R. Shivashankar: None. M.K. Ali: None. M. Kadir: None. D. Prabhakaran: None. R.L. Hanson: None. V. Mohan: None. E. Selvin: None. N. Tandon: None.

Funding
National Heart, Lung, and Blood Institute; Department of Health and Human Services (HHSN268200900026C); United Health Group, Minneapolis, MN; National Institute of Diabetes and Digestive and Kidney Diseases (P30DK111024)
161-OR: Autoantibodies Directed to Deamidated Post-translationally Modified IA-2 Epitopes in Type 1 Diabetes
Authors: ACEVEDO-CALADO MARIA J. , PIETROPAOLO SUSAN , YU LIPING , MICHELS AARON W. , PIETROPAOLO MASSIMO 
Published: June 2019

Autoimmune disorders such rheumatoid arthritis (RA) harbor autoantibodies against a variety of post-translationally modified (PTM) proteins. We aimed to investigate whether PTM epitopes of IA-2, a major autoantigen related to type 1 diabetes (T1D), are targeted by autoantibody responses. The extracellular domain of IA-2 (IA-2-ec) was synthesized incorporating deamidated amino acid residues (IA-2ec-PTM) previously found to elicit T cell responses in T1D patients. IA-2ec-PTM was then subjected to immunoprecipitation with sera from T1D patients. Notably, autoantibody reactivity towards IA-2ec-PTM was present in 28% of T1D patients as compared to ~9% of serum reactivity against the native IA-2ec. The area under the ROC curve (ROC AUC) of IA-2ec-PTM autoantibodies revealed that these autoantibodies can adequately distinguish between T1D patient and control groups (ROC AUC: 0.7132; P &lt; 0.0001). Relatives of T1D probands (from the TrialNet Pathway to Prevention Study) carrying both IA-2ec-PTM AAb and the high-risk HLA-DRB1*04-DQB1*03:02 haplotype progressed rapidly to onset of T1D (Stage 3) compared to those relatives who did not carry these immunologic abnormalities (P = 0.003). Understanding the mechanisms underlying PTMs of islet autoantigens, such as IA-2ec-PTM, is critical to develop new research to determine the ability of modified epitopes to induce islet autoimmunity, their potential role as biomarkers of islet cell injury as well as breaking immune tolerance to islet cell antigens through neo-antigen formation.

Disclosure
M.J. Acevedo-Calado: None. S. Pietropaolo: None. L. Yu: None. A.W. Michels: Stock/Shareholder; Self; IM Therapeutics. M. Pietropaolo: None.

Funding
National Institutes of Health
1611-P: Diabetes by Air, Land, and Sea: Effects of Military Deployment on A1c and BMI
Authors: FOLARON IRENE , TRUE MARK W. , WARDIAN JANA L. , KAZANIS WILLIAM H. , TATE JOSHUA M. , SAUERWEIN TOM J. , GRAYBILL SKY , CLERC PHILIP G. , JENKINS CRAIG 
Published: June 2019

United States (U.S.) military service members with diabetes (DM) are restricted from working in austere locations due to concerns over potential glycemic decompensation. However, the policies guiding these duty restrictions may be overcautious and are unsubstantiated by systematic analysis. To address this knowledge gap, we conducted a retrospective study characterizing service members with DM who deployed overseas and analyzed changes in their A1c and BMI before and after deployment. In all branches of the U.S. military (Air Force, Army, Marines, Navy), active duty service members with DM completed 11,206 individual deployments lasting ≥90 days between 2004-2017. Of those, 668 (6%) completed a pre- and post-deployment A1c check within 90 days of departure and repatriation. The majority (81.3%) did not have an A1c check before and/or after deployment. For those with A1c values prior to deployment, 64.5% had an A1c &lt; 7%, 20.2% had an A1c between 7-7.9%, 8.4% had an A1c between 8-8.9%, and 6.9% had an A1c ≥ 9%. Most (61.2%) were taking DM medications, of which metformin was the most common (66.2%), followed by sulfonylureas (22.5%). Despite policy restrictions, 6% deployed on insulin. Coincident hypertension (29%) and lipid disorders (33.1%) were common, but ≤ 1% had microvascular complications. BMI was checked pre- and post-deployment on 3083 individual deployments (28%). Mean A1c and BMI did not significantly change pre- and post-deployment (A1c pre- 6.89% vs. post- 6.93%, p = 0.58; BMI pre- 28.9 kg/m2vs. post- 28.7 kg/m2, p = 0.14). U.S. military medical policies restrict deployments for service members with DM due to a perceived risk of decompensation when medical resources are scarce. However, our data demonstrate that A1c and BMI do not significantly change, suggesting that select service members with DM can maintain adequate glycemic control during deployments. The lack of A1c surveillance for the majority of service members with DM surrounding deployment is concerning and should prompt changes in policy.

Disclosure
I. Folaron: None. M.W. True: None. J.L. Wardian: None. W.H. Kazanis: None. J.M. Tate: None. T.J. Sauerwein: Speaker's Bureau; Self; AstraZeneca, Merck & Co., Inc. S. Graybill: None. P.G. Clerc: None. C. Jenkins: None.
1612-P: Insulinogenic Index and HOMA-ß Are Independent Risk Factors for Future Type 2 Diabetes
Authors: SATO KYOKO K. , HAYASHI TOMOSHIGE , UEHARA SHINICHIRO , ONISHI YUKIKO , LEONETTI DONNA L. , KAHN STEVEN E. , FUJIMOTO WILFRED Y. , BOYKO EDWARD J. 
Published: June 2019

β-cell dysfunction is major risk factor for type 2 diabetes. As HOMA-β reflects fasting β-cell function and insulinogenic index reflects early phase insulin response during an oral glucose tolerance test (OGTT), these two indices represent different aspects of insulin and glucose metabolism. It is not known whether HOMA-β and insulinogenic index are independently associated with type 2 diabetes risk. In a prospective cohort study, 415 nondiabetic Japanese-American men and women were followed for 10-11 years. Insulin sensitivity was assessed by HOMA-IR. β-cell activity was assessed by HOMA-β [fasting plasma insulin (μU/mL) × 360/(fasting plasma glucose (mg/dL) - 63)] and the insulinogenic index [Δinsulin (30-0 min) (μU/mL)/Δglucose (30-0 min) (mg/dL)] obtained during a 75-g OGTT. Type 2 diabetes was diagnosed as fasting plasma glucose level ≥126 mg/dL, 2-hour glucose level ≥200 mg/dL, or taking glucose-lowering medications. Logistic regression analysis was used to estimate odds ratios (OR) of incident diabetes. A total of 95 participants developed type 2 diabetes over 10-11 years. Insulinogenic index and HOMA-β were independently associated with the risk of type 2 diabetes. In multiple-adjusted models that included insulinogenic index, HOMA-β, HOMA-IR, age, BMI, gender, and family history of diabetes, OR of future type 2 diabetes for tertile 2 and 3 of insulinogenic index were 0.43 (95% CI, 0.22-0.85) and 0.31 (0.14-0.67), respectively, compared to tertile 1, and those for tertile 2 and 3 of HOMA-β were 0.31 (0.14-0.69) and 0.25 (0.10-0.63), respectively, compared to tertile 1. HOMA-IR was also associated with the risk of type 2 diabetes independent of these two indices. OR of tertile 2 and 3 of HOMA-IR were 1.75 (0.82-3.74) and 9.17 (3.78-22.28), respectively, compared to tertile 1.
In conclusion, both higher insulinogenic index and HOMA-β were independently associated with a lower risk of type 2 diabetes independent of insulin sensitivity.

Disclosure
K.K. Sato: None. T. Hayashi: None. S. Uehara: None. Y. Onishi: None. D.L. Leonetti: None. S.E. Kahn: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S. Consultant; Self; Neurimmune. Other Relationship; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S. W.Y. Fujimoto: None. E.J. Boyko: None.
1616-P: Mortality Rates due to Diabetes Mellitus in Costa Rica, 2007-2017
Authors: JIMENEZ-MONTERO JOSE G. 
Published: June 2019

Introduction: Diabetes mellitus is a major health problem in Costa Rica. Its prevalence is rapidly increasing achieving 12.8% and represents a burden for the health system. Changes in mortality due to diabetes have not being fully evaluated.
Objective: To describe specific diabetes mortality and life expectancy in diabetics from 2007 to 2017.
Material and Methods: Death certificates (classification CIE-10) were obtained from the Instituto Nacional de Estadistica y Censos from 2007 to 2017. Total mortality, standardized diabetes mortality rates per 100.000 habitants (SDMR) and deaths due to diabetic nephropathy were assessed. The years of life lost (YLL) due to diabetes was determined using data of life expectancy at birth per 1000 habitants. Gini coefficient, Lorenz curve, Index of Human Development and the Public Morbidity Report were employed to explain changes in diabetes mortality.
Results: Total mortality in Costa Rica remained invariable through the study period. From 2006 to 2014 the SDMR was constant (14.5 to 15.2) However, SDMR steadily peak from 15.2 to 26.3 during the last three years. Compared to males, SDMR was higher in females, the excess of mortality due to diabetes in females ranged from 1.7 to 4.8 deaths per 100.000 habitants. Up to 2013 the YLL ranged from 30 and 20 deaths per 1000 habitants in females and males, respectively. Nonetheless, YLL increased in females and males to 48.9 and to 34.3 at the end of the study. Deaths associated to diabetic renal disease increased. Index of Human Development did not explain the increase in diabetes mortality. Public Health Care Coverage in diabetics reached 40%. HbA1c, LDL and blood pressure control goals were achieved in 41%, 35% and 52%, respectively and 11% of diabetics accomplished the triple goal. Low Public Health Care Coverage in diabetics was seen in two provinces with the higher SDMR.
Conclusions: In Costa Rica deficient coverage and poor diabetes management may explain the changes in SDMR.

Disclosure
J.G. Jimenez-Montero: None.
162-OR: Identification of Autoantibodies to ZnT8 Extracellular Epitope(s) in Patients with T1D
Authors: GU YONG , MERRIMAN CHENGFENG , WENZLAU JANET M. , YU LIPING , FU DAX 
Published: June 2019

Previous studies demonstrate ZnT8 is displayed on the β-cell surface upon insulin secretion and IgG from ZnT8A-positive T1D patient sera stains the surface of live pancreatic β-cells. To further identify autoantibodies (AAb) to the ZnT8 extracellular epitope(s) (ZnT8ec) and to develop a ZnT8ec AAb assay, we first stabilized its native structure without the N-terminal domain (a.a 66-369; R325 or W325) by forming ZnT8-intracellular domain-Ab (ZnT8ic) complexes prior to release from liposome membranes. Sulfo-tagged ZnT8-Ab complexes were used as antigen in our electrochemiluminescence (ECL) AAb assay to analyze 130 sera (96 T1D patients, 22 T2D patients and 12 normal controls). Autoantibodies to ZnT8ec were identified in T1D patient sera by cross-reactivity of sera previously identified as exclusively ZnT8R or W positive, and ZnT8A negative sera. The prevalence of ZnT8ec AAbs in T1D patients was 21% (22/96: 5/37 of R+ sera, 7/24 of W+ sera and 8/35 of ZnT8A- sera) compared to 1/22 T2D patients and 0/12 normal controls. These are the first biochemically defined AAbs from T1D sera reported to target the β-cell surface. Further analysis of the role of these autoantibodies in β-cell autoimmunity and T1D etiopathology will be interesting and important for future studies.

Disclosure
Y. Gu: None. C. Merriman: None. J.M. Wenzlau: None. L. Yu: None. D. Fu: None.
1622-P: HbA1c, Blood Pressure, and Cholesterol (ABC) Control in Patients with Type 2 Diabetes from Tibet in China
Authors: CHENGHUI ZHANG , MINGXIA LI , SUYUAN WANG , YUNHONG WU 
Published: June 2019

Aim: Diabetes has rapidly become an epidemic all over the world. In 2013, the prevalence of type 2 diabetes (T2D) in China was reported to be 10.4%. The Qinghai-Tibet Plateau is the world’s highest plateau, people lived in there usually have a high-calorie diet and low fruit and vegetable intake. The aim of this study was to describe the current control of HbA1c (A), blood pressure (B) and LDL-c (C) in patients with T2D from Tibet based on electronic medical records.
Methods: Patients aged 18-79 years with T2D documented from 2014 to 2018 were enrolled in this study. Clinical and biochemical characteristics were collected from EMRs. Control criteria were defined base on the 2017 Chinese Guidelines for the Prevention and Treatment of type 2 diabetes.
Results: A total of 1999 patients with type 2 diabetes were included in the study. The mean (SD) age of the subjects was 55.2 (10.5) years. The median diabetic duration was 7.0 (range: 0.1-32) years and 879 (43.9%) patients were female. Among patients, 653 (32.7%) patients had a normal weight (BMI &lt; 24 Kg/m2), 874 (43.7%) patients were overweight (24 ≤ BMI &lt; 28Kg/m2) and 472 patients were obesity (BMI ≥ 28 Kg/m2). Only 321 (16.1%) patients had controlled HbA1c concentration below 7.0%, 965 (48.3%) had poor controlled HbA1c (HbA1c &lt; 9%). The prevalence of hypertension was 46.8% and 742 (37.1%) patients had controlled blood pressure (systolic blood pressure &lt;130 mmHg and diastolic blood pressure &lt; 80 mmHg). Controlled LDL-c concentration (&lt;1.8 mmol/L with coronary heart disease and 2.6 mmol/L without the disease) was found in 1046 (52.3%) patients. In all patients, 848 (42.4%) patients achieved at least one target, 526 (26.3%) patients achieved at least two targets and only 70 (3.5%) patients achieved all three targets.
Conclusions: Despite the potential selection bias, the glycemic controls is quite low in the present study, even few patients achieved all ABC targets. More intensive T2DM management with complementary efforts is warranted in this population.

Disclosure
Z. Chenghui: None. L. Mingxia: None. W. Suyuan: None. W. Yunhong: None.